- Home>
- Specialties>
- HIV/AIDS Clinical Care>
- Resistance
Search for Resistance in HIV/AIDS Clinical Care
Physician-authored summaries on the latest research on resistance, editorials on resistance, and perspectives on resistance - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 548 results - Relevance
- Date
You searched for: resistance in HIV/AIDS
-
Resistance Development with Tenofovir/FTC vs. AZT/3TC Free
- October 19, 2009
- Jonathan Z. Li, MD, and Paul E. Sax, MD
- HIV/AIDS
In a comparative clinical trial, patients receiving tenofovir/FTC were less likely to develop resistance mutations during virologic failure than were those receiving AZT/3TC.- Reviewing:
- Margot NA et al., J Acquir Immune Defic Syndr 2009 Oct 1; 52:209.
-
HIV Resistance Testing Is Associated with Improved Survival
- July 27, 2009
- Paul E. Sax, MD
- HIV/AIDS
HIV outpatients who underwent resistance testing were less likely to die than their untested counterparts during about 3 years of follow-up, but no single factor is likely to explain this observational finding.- Reviewing:
- Palella FJ Jr et al., Ann Intern Med 2009 Jul 21; 151:73. Volberding P., Ann Intern Med 2009 Jul 21; 151:135.
-
Another Benefit to Starting ART Early: Lower Risk for Resistance Free
- July 13, 2009
- Paul E. Sax, MD
- HIV/AIDS
Among patients who experienced virologic rebound in this observational cohort study, risk for resistance was decreased in those who initiated ART at CD4 counts >350 cells/mm3.- Reviewing:
- Uy J et al., J Acquir Immune Defic Syndr 2009 Aug; 51:450.
-
Failure on First-Line Lopinavir/r Monotherapy: High Rates of PI Resistance
- July 13, 2009
- Keith Henry, MD
- HIV/AIDS
Results from the MONARK trial do not support lopinavir/r monotherapy as first-line treatment for HIV infection, because it was both less effective and more likely to cause major PI resistance than triple therapy with lopinavir/r, AZT, and 3TC.- Reviewing:
- Delaugerre C et al., Antimicrob Agents Chemother 2009 Jul; 53:2934.
-
How Deep Are the Reservoirs of Antiretroviral Resistance?
- June 8, 2009
- Charles B. Hicks, MD
- HIV/AIDS
An assay that measures HIV-derived DNA in peripheral blood mononuclear cells detected more resistance mutations in more patients than did standard serum resistance testing.- Reviewing:
- Ellis GM et al., J Acquir Immune Defic Syndr 2009 Apr 24;:
-
Are Resistance Rates Rising or Holding Fairly Stable?
- March 23, 2009
- Abigail Zuger, MD
- HIV/AIDS
A study from Switzerland indicates that resistance rates might have actually decreased since 1999.- Reviewing:
- von Wyl V et al., Clin Infect Dis 2009 Apr 1; 48:979.
-
Defining Resistance in HIV-2 Free
- February 2, 2009
- Judith Feinberg, MD
- HIV/AIDS
In a small study from Senegal, more than half of HIV-2–infected patients had genetic evidence of NRTI or PI resistance; specific mutations were dissimilar to those commonly seen with HIV-1.- Reviewing:
- Gottlieb GS et al., Clin Infect Dis 2009 Feb 15; 48:476.
-
When First Regimens Fail, Resistance Patterns Vary
- September 11, 2008
- Abigail Zuger, MD
- HIV/AIDS
Genotypic drug resistance is widespread following failure of initial therapy with NNRTIs but not with boosted PIs.- Reviewing:
- Gupta R et al., Clin Infect Dis 2008 Sep 1; 47:712. Campbell TB., Clin Infect Dis 2008 Sep 1; 47:723.
-
Highly Sensitive Resistance Testing: Relevant, but Ready for the Clinic?
- August 25, 2008
- Charles B. Hicks, MD
- HIV/AIDS
Low-frequency mutations are relatively common among treatment-naive patients and seem to influence outcome, but the more-sensitive assays to detect them aren’t yet ready for clinical use.- Reviewing:
- Johnson JA et al., PLoS Med 2008 Jul 29; 5:e158.
-
Antiretroviral Drug Resistance Testing — Updated Guidelines from the IAS–USA
- July 14, 2008
- Charles B. Hicks, MD
- HIV/AIDS
The latest guidelines include updated information on resistance to both old and new drugs and provide specific recommendations for the clinical application of resistance testing.- Reviewing:
- Hirsch MS et al., Clin Infect Dis 2008 Jul 15; 47:266.
-
Does Viral-Load Testing Reduce Drug Resistance in Resource-Poor Settings? Free
- May 5, 2008
- Renslow Sherer, MD
- HIV/AIDS
Despite viral-load testing, high levels of drug resistance at first virologic failure were found in KwaZulu-Natal, South Africa.- Reviewing:
- Marconi VC et al., Clin Infect Dis 2008 May 15; 46:1589.
-
More Evidence That Transmitted Resistance Does Matter — An Analysis from ACTG 5095
- March 31, 2008
- Charles B. Hicks, MD
- HIV/AIDS
Having NNRTI resistance at baseline more than doubles the risk for virologic failure on initial efavirenz-based regimens.- Reviewing:
- Kuritzkes DR et al., J Infect Dis 2008 Mar 15; 197:867.
-
Transmitted HIV Drug Resistance in Pregnant Women
- October 22, 2007
- Sonia Nagy Chimienti, MD
- HIV/AIDS
Data from the Women and Infants Transmission Study reinforce the importance of genotypic resistance testing in treatment-naive HIV-infected pregnant women.- Reviewing:
- Paredes R et al., AIDS 2007 Oct 1; 21:2103.
-
Darunavir and Genotypic Resistance — An Ongoing Story
- October 15, 2007
- Charles B. Hicks, MD
- HIV/AIDS
Most patients with a history of PI treatment probably harbor virus that is susceptible to darunavir.- Reviewing:
- Mitsuya Y et al., J Infect Dis 2007 Oct 15;: Haubrich R., J Infect Dis 2007 Oct 15;:
-
Transmitted Resistance Among Newly HIV-Infected Patients: Has It Peaked?
- May 21, 2007
- Charles B. Hicks, MD
- HIV/AIDS
A comprehensive report from the U.K. indicates a recent decline in the rate of transmitted drug resistance.- Reviewing:
- UK Collaborative Group on HIV Drug Resistance., AIDS 2007 May 11; 21:1035-9.
-
Prevalence and Predictors of Triple-Class Drug Resistance
- May 7, 2007
- Helmut Albrecht, MD
- HIV/AIDS
The development of triple-class resistance is rare in patients who initiate antiretroviral therapy with a regimen that includes either a potent NNRTI or a boosted PI.- Reviewing:
- Napravnik S et al., AIDS 2007 Apr 23; 21:825-34.
-
Treatment + Ongoing Viremia = More Resistance
- April 23, 2007
- Paul E. Sax, MD
- HIV/AIDS
Despite stable CD4-cell counts and viral loads, patients with detectable viremia on antiretroviral therapy accumulate resistance mutations and lose future treatment options.- Reviewing:
- Cozzi-Lepri A et al., AIDS 2007 Mar 30; 21:721-32.
-
Evolution of Resistance During Treatment Failure
- January 12, 2007
- Charles B. Hicks, MD
- HIV/AIDS
In a retrospective study, new major PI-associated mutations emerged more rapidly during treatment failure than did new TAMs, but this difference was apparent only in the absence of 3TC.- Reviewing:
- Goetz MB et al., J Acquir Immune Defic Syndr 2006 Dec 15; 43:541-9.
-
Transmitted HIV-Drug Resistance in Adolescents
- November 27, 2006
- Paul E. Sax, MD
- HIV/AIDS
In a small nationwide survey in the U.S., a striking 18% of recently infected adolescents had genotypic evidence of transmitted drug resistance.- Reviewing:
- Viani RM et al., J Infect Dis 2006 Dec 1; 194:1505-9.
-
More Support for Pretreatment Resistance Testing in All Patients
- June 14, 2006
- Charles B. Hicks, MD
- HIV/AIDS
Data from Germany support the new DHHS recommendation to perform genotypic resistance testing in all treatment-naive patients.- Reviewing:
- Oette M et al., J Acquir Immune Defic Syndr 2006 Apr 15; 41:573-81.
Sort by:
Items 1 to 20 of 548 results - Relevance
- Date
